Tesamorelin

Product Details

Overview

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), more precisely a human GRF analog engineered to stimulate endogenous growth hormone secretion through the GHRH receptor on pituitary somatotroph cells. Unlike exogenous administration of growth hormone itself, tesamorelin does not function as GH replacement; rather, it acts as a GH secretagogue, stimulating the body’s own somatotropic axis. According to FDA documentation, tesamorelin increases GH secretion and subsequently raises IGF-1 and IGFBP-3 levels (accessdata.fda.gov).

What it is and how it works

After binding to the GHRH receptor (GHRH-R) in the anterior pituitary, tesamorelin activates the physiologic somatotropic axis, increasing both pulsatile and basal GH secretion and, secondarily, IGF-1 levels. Importantly, its mechanism operates upstream through the intact hypothalamic–pituitary system rather than by directly providing exogenous GH. This distinction is scientifically and clinically relevant because GHRH analogs preserve a more physiologic pulsatile endocrine pattern. Reviews of GHRH biology and tesamorelin emphasize that this form of stimulation increases endogenous GH secretion without changing pulse frequency as much as altering pulse amplitude and overall GH/IGF-1 axis activity (PMC).

Effects confirmed by research

The best-documented effect of tesamorelin is reduction of visceral adipose tissue (VAT) together with activation of the GH/IGF-1 axis. In pooled analyses of two multicenter, double-blind, placebo-controlled phase 3 trials in HIV-infected patients with excess abdominal fat, tesamorelin significantly reduced VAT and waist circumference while increasing IGF-1. This represents the strongest clinical evidence base supporting tesamorelin (OUP Academic). Another major research area is hepatic steatosis / NAFLD in the setting of HIV. A randomized, double-blind, multicenter trial demonstrated that tesamorelin reduced liver fat fraction and slowed fibrosis progression compared with placebo. This is important because tesamorelin’s biological activity extends beyond body composition alone and reaches metabolic and hepatic pathways linked to GH/IGF-1 signaling (PMC). Research also suggests that tesamorelin may beneficially affect the lipid profile and selected cardiometabolic markers. Reviews and clinical analyses have described improvements in dyslipidemia, reductions in certain cardiovascular risk markers, and changes in adipokines or inflammatory markers in parallel with visceral fat reduction. These findings, however, should be interpreted within the specific studied populations—particularly HIV-associated abdominal adiposity—and should not be overstated beyond the available evidence (PMC).

Safety and endocrine profile

Unlike less selective GH secretagogues, tesamorelin acts primarily through GHRH-R, and FDA labeling indicates that in clinical trials it did not produce clinically meaningful changes in other pituitary hormones such as TSH, LH, ACTH, or prolactin. On the other hand, it reliably increases IGF-1, which is why FDA documents recommend monitoring for persistent IGF-1 elevation and caution in patients with diabetes or risk of impaired glucose tolerance. In a 12-week randomized trial in patients with type 2 diabetes, tesamorelin did not significantly worsen glycemic control, but safety interpretation should remain appropriately conservative given the metabolic context and endocrine effects involved (PMC).

Professional scientific description

From a scientific standpoint, tesamorelin is a stabilized GHRH analog whose principal research-supported effect is activation of the GH/IGF-1 axis, followed by downstream changes in visceral adiposity, metabolic markers, and in some populations hepatic steatosis. It is most accurately described as a physiologically oriented stimulator of the somatotropic axis, rather than as growth hormone itself. Compared with exogenous GH, its pharmacologic logic is based on stimulating endogenous regulation, which is precisely why it has become a focus of metabolic and endocrine research (PMC). For scientific or educational content, the three most accurate pillars are: stimulation of endogenous GH secretion through the GHRH receptor, clinical reduction of visceral fat together with activation of the GH/IGF-1 axis, relevant research in HIV-associated abdominal adiposity, metabolism, and liver fat biology (OUP Academic).

References

Falutz, J., et al. Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials. Journal of Clinical Endocrinology & Metabolism. 2010. Stanley, T. L., et al. Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men. 2010. Stanley, T. L., Grinspoon, S. K. Effects of Growth Hormone-Releasing Hormone on Visceral Fat, Metabolic Markers, and Cardiovascular Risk. 2014. Stanley, T. L., et al. Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients with Abdominal Fat Accumulation.. Stanley, T. L., et al. Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV. Lancet HIV. 2019. Clemmons, D. R., et al. Safety and Metabolic Effects of Tesamorelin, a Growth Hormone-Releasing Hormone Analogue, in Patients with Type 2 Diabetes.. U.S. Food and Drug Administration. Tesamorelin prescribing information. (accessdata.fda.gov).